Search
for

    GlossaryGoserelin

    reduces sex hormone production to treat hormone-sensitive cancers

    Goserelin, also known by the brand name Zoladex, is a type of medication called a gonadotropin-releasing hormone (GnRH) agonist. It is used to treat hormone-sensitive cancers such as prostate cancer in men and breast cancer in premenopausal women, as well as certain benign gynecological conditions like endometriosis. Goserelin works by reducing the production of sex hormones (testosterone and estrogen), which can help slow the growth of hormone-dependent tumors.

    Related Terms

    Learn

    5 / 801 results

      learn RU58841

      a potent but unapproved and potentially problematic topical anti-androgen

      learn Estradiol

      an estrogen promoting hair regrowth more commonly used in women

      learn Fluridil

      a topical anti-androgen with less systemic involvement

    Research

    5 / 154 results

    Community Join

    5 / 1000+ results

      community Estradiol mesotherapy / idea feedback

      in Female  6 upvotes 1 year ago
      The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community A concern regarding the upcoming androgen degrader drug GT20029

      in Chat  11 upvotes 1 year ago
      GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

      community GT20029 - Promising phase II results

      in Research/Science  15 upvotes 1 year ago
      GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.